Navigation Links
John Sundahl Publicly Announces His Romance With Britney

Real estate investor John Sundahl has announced that he is going around with pop singer Britney Spears.

Sundahl, a recovering alcoholic, said that his romance with Spears began after their meeting at an Alcoholics Anonymous meeting in Los Angeles.

He stressed that he knew Spears also loved him, and corroborated his claim by revealing how the singer helped him recover from bowel surgery recently.

"When I was in the hospital, she sat with me and held my hand all night long. She even sang and hummed to me while I was practically unconscious," Contactmusic quoted him as telling National Enquirer.

"I love being around her. She's a sweet, caring girl and a good mom," he added.

The wealthy 38-year-old also revealed that Spears sought him out for counselling sessions after leaving rehab at Promises in Malibu earlier this year (07), and then started attending AA meetings he staged.

He further said that Spears' estranged husband Kevin Federline might be devastated by the new of their romance, as the aspiring rapper's lawyers his romance initially him to testify against the pop star.


'"/>




Page: 1

Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
(Date:7/25/2008)...e/ -- Klafter & Olsen LLP has filed a,class action...re" or the,"Company") (Nasdaq: ARTC ) and certain...e Western District of Texas on behalf of all perso...roCare from January 24, 2008,through July 18, 2008...ll,persons or entities who purchased call options ...
(Date:7/25/2008)...iretroviral therapy may be due to genetic factors ...A new study challenges the long-held belief that t...em,s ability to restore itself after HIV patients ...apy (HAART). , From 50 percent to 90 percent of...V. Intravenous drug use is the main cause of both ...
(Date:7/25/2008)...- BeaconEquity.com announces the,availability of T...rs can view all of the daily trading notes for fre...,s Trade Alerts include: DUSA Pharmaceuticals Inc..... (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), A...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
(Date:7/25/2008)...gnificant Improvements in Members, Health, ATLANT...er in health,care quality management solutions for...s entered into a long-term agreement with Wellmark...tion on Quality(SM) Incent and,Reward Best Practic...d,primary care clinicians to promote improved qual...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...a common fear in women that their sexual performan..., an international journal of obstetrics and gynec...irth affects a woman's sexual function in the long... women who had given birth for the first time. The...
...inia Tech researcher Stefan Duma has been named as...rs for his biomechanics innovations.// Technology...mechanical engineering and founding director of th...ury Biomechanics, to the 2006 'TR35' list of the t...
... publisher John Wiley & Sons, Inc., confirms their...AASLD for providing subscriptions of their journal...c., had announced on the 6th of September their pl... American Society for Paediatric Gastroenterology,...
...chers at St. Louis Children's Hospital and Washing...e requested authorities not to allow children unde...ATVs). This call was issued after a 10-year review...perience or training in driving motorized vehicles...
Other Medicine News:Health News:A young scientist recognized for biomechanics innovations 2Health News:A young scientist recognized for biomechanics innovations 3Health News:Call To Ban Use Of ATVs By Children 2
(Date:7/23/2008)...ewswire/ -- The following was,released by the U.S....g Member Smith, and Members of the Committee.,Than...e I appeared before this Committee almost six mont...the talented and dedicated professionals,at the Ju...have come to,appreciate that much more deeply thei...
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Study finds recent trend of growing US disparities in health not inevitable 12680 1Study finds recent trend of growing US disparities in health not inevitable 12680 2Study finds recent trend of growing US disparities in health not inevitable 12680 3Krill discovered living in the Antarctic abyss 2314 1Krill discovered living in the Antarctic abyss 2314 2Pharsight to Present at eClinical Forum 12678 1Pharsight to Present at eClinical Forum 12678 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 1HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 3HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 4HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 5HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 6HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 7HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 8HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 9HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 10HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 11HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 12HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 13HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 14HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 15HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 16HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 17HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 18HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 19HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 20HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 21HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 22
...nspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today ...al trial comparing epinastine nasal,spray and plac...or,the primary endpoint of improvement in total na...ved in the trial, with the higher,dose (0.1%) achi...ty L. Shaffer, Ph.D., Inspire,s President and CEO,...
...tCall/ -- ISTA,Pharmaceuticals, Inc., today announ....S. Phase II/III clinical study of bepotastine for...dy evaluated two,concentrations of bepotastine, ea...ndpoints of the study were the assessment of,effic... redness.,The preliminary results of the study dem...
Other Medicine Technology:Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 2ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 3ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 5
Angled for temporal approach. Solid 14 mm blades. Dull finish.
Solid 8 mm blades. Dull finish. Most popular size or model.
Closed wire 5 mm blade with a wing tip twist giving the surgeon better on-axis accessibility.
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish.
Medicine Products: